(PharmaNewsWire.Com, July 22, 2020 ) The global digital pathology market is projected to reach USD 1,139 million by 2025 from USD 613 million in 2020, at a CAGR of 13.2% during the forecast period. The growth in this market is driven by the increasing adoption of digital pathology to enhance lab efficiency, rising prevalence of cancer, growing application of digital pathology in drug development & companion diagnostics, and increasing initiatives by the industry players. However, the high cost of digital pathology systems is expected to restrict market growth to a certain extent. Lack of trained pathologists may also challenge market growth in the coming years.
The digital pathology market is well established owing to the dominance of prominent market players, such as Leica Biosystems (US), Koninklijke Philips N.V. (Netherlands), and Hamamatsu Photonics K.K. (Japan). Other prominent players in this market include Roche (Switzerland), 3DHISTECH (Hungary), Apollo Enterprise Imaging (US), XIFIN (US), Huron Digital Pathology (Canada), Visiopharm A/S (Denmark), Corista (US), Indica Labs (US), Objective Pathology Services (Canada), Sectra AB (Sweden), OptraSCAN (India), Glencoe Software (US), KONFOONG BIOTECH INTERNATIONAL CO., LTD (China), Inspirata Inc. (US), Mikroscan Technologies (US), Proscia Inc. (US), and Kanteron Systems (Spain).
To know about the assumptions considered for the study download the pdf brochure
Leica Biosystems (US) was the largest player in the digital pathology market in 2019. The company offers an extensive range of digital pathology solutions, such as scanners, software, image analysis software, and various other services. Leica Biosystems aims to be an end-to-end solution provider by providing researchers and laboratories with products that will aid in the pathology process.
The company focuses on organic and inorganic growth strategies to maintain its position in the market and expand its global presence. The company focuses on product launches in order to create a strong foothold in the market. In 2019, Leica Biosystems launched the Aperio GT 450, a next-generation digital pathology scanner. Similarly, in 2018, the company received approval for its scanner, the Aperio LV1 IVD, to be sold in Europe, Canada, Australia, and New Zealand.
Koninklijke Philips N.V. (Netherlands) is the second-leading player in the global digital pathology market. The company has a strong geographical presence in Europe, North America, the Asia Pacific, and Africa. The company offers scanners, software, communication systems, and storage systems for digital pathology. Philips strategically focuses on collaborating and partnering with other market players to launch technologically advanced products, and to expand its presence globally. In line with this, the company collaborated with Paige (US) to deliver AI to clinical pathology diagnostics in 2019. This collaboration is expected to deliver clinical-grade AI applications to pathology laboratories. Similarly, in 2017, the company partnered with PathAI (US) in order to jointly develop solutions to improve the precision and accuracy of the routine diagnosis of cancer and other diseases. Moreover, this partnership enables Philips to apply AI to massive pathology data sets for informed diagnostic and treatment decisions.
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
